View in Other Languages

Mesoblast Limited

ASX:MSB ISIN:AU000000MSB8

 Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

  

News

Mesoblast Limited (ASX:MSB) in Position of Considerable Strength

🕔8/24/2011 10:00:00 AM 5249

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million.

Read Full Article

Mesoblast Limited (ASX:MSB) Performed First Minimally Invasive Procedure for Lumbar Disc Repair

🕔8/22/2011 8:32:00 AM 3203

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the first minimally-invasive lumbar disc procedure had been successfully performed in the Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell product for the treatment of low back pain and degenerative disc disease. The outpatient procedure lasted less than 20 minutes, with the patient fully awake and under light sedation. The patient was shortly discharged and there were no complications.

Read Full Article

Mesoblast Limited (ASX:MSB) Heart Failure Trial Selected for Presentation in Special Session of American Heart Association Annual Conference Melbourne, Australia on 15 August 2011

🕔8/15/2011 9:40:40 AM 3304

Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.

Read Full Article

Mesoblast Limited (ASX:MSB) Receive FDA Clearance for Phase 3 Bone Marrow Transplant Trial

🕔7/7/2011 9:23:00 AM 5239

Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission.

Read Full Article

US Food and Drug Administration Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial to Treat Degenerative Disc Disease

🕔6/29/2011 9:22:00 AM 6437

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell (MPC) product for the treatment of degenerative disc disease.

Read Full Article

Mesoblast Limited (ASX:MSB) Key Product Franchises Featured at Nomura Asia Equity Forum

🕔6/14/2011 12:26:00 PM 4383

Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum.

Read Full Article

Mesoblast Limited (ASX:MSB) Revascor Increases Blood Supply to Damaged Heart Muscle

🕔6/9/2011 9:39:00 AM 6971

Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.

Read Full Article

Mesoblast Limited (ASX:MSB) To Present At Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference

🕔6/6/2011 10:19:00 AM 7468

Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum.

Read Full Article

Mesoblast Limited (ASX:MSB) Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications

🕔5/24/2011 9:40:00 AM 4558

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.

Read Full Article

Mesoblast Limited (ASX:MSB) Included In Standard And Poor/ASX 200 Index

🕔4/18/2011 9:41:00 AM 3899

Standard and Poor's Indices has announced that regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.

Read Full Article
###

170,364 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 101) (Last 30 Days: 438) (Since Published: 46665) 

Company Data

    Headquarters
  • Level 39
    55 Collins Street
    Melbourne 3000
    AUSTRALIA
  • Telephone
  • +61-3-9639-6036 
  • Fax
  • +61-3-9369-6030 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2004/12/16 
  • Homepage
  • www.mesoblast.com

Presentations

Social Media